 "EUL to Covaxin from WHO expected in first week of August: Report")
The World Health Organisation (WHO) is likely to take a decision on Emergency Use Listing (EUL) of Bharat Biotech's Covaxin and announce it in the first week of August.
A WHO pre-qualification, or EUL, is necessary for a vaccine company to supply vaccines for global facilities such as Covax or international procurement.
The WHO has approved vaccines Pfizer-BioNTech, AstraZeneca- SK Bio/SII, Johnson & Johnson Janssen, Moderna and Sinopharm for emergency use.
The indigenous vaccine showed 63.6 per cent efficacy against the Delta variant of Covid-19, which has spread in many other countries.
Covaxin demonstrated 93.4 per cent efficacy against severe symptomatic Covid-19 and 63.6 per cent against asymptomatic Covid-19.
The trial was conducted on 25,800 subjects, and the data submitted to the Subject Expert Committee (SEC) showed the vaccine was "well-tolerated.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)